Compare Home Depot Inc (HD) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Novartis AG — how do they compare? Home Depot Inc trades at $296.37 (market cap $285.11B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Home Depot Inc and Novartis AG are close in size by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Novartis AG for 82 Days on average.
| HD | NVS | |
|---|---|---|
Market Cap | $285.11B | $274.00B |
Volume | 5,334,053 | 1,852,137 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $168.62 |
52-Week Low | $281.15 | $121.80 |
Typical Hold Time | 139 Days | 82 Days |
Enterprise Value | $345.59B | $315.32B |
Dividend Yield | 3.26% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $285.77, down 0.32% with bearish technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 104.3%, net margin 8.41%). Revenue grew to $159.51B in 2025, though margins face pressure from housing market headwinds. Analysts maintain a bullish consensus with a $379.93 price target (58.7% buy ratings). Recent institutional activity shows mixed positioning amid weak big-ticket demand.
HD offers long-term value with analyst upside of 33% but faces near-term risks from rising mortgage rates and margin compression. The Pro business and digital initiatives provide growth levers, while technical weakness suggests cautious entry points. Investors should weigh strong cash flow generation against cyclical housing exposure.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
